BRIEF-Oncolytics Biotech U.S.-listed shares up in premarket after lung cancer drug meets main goal of mid-stage study

Thu Mar 28, 2013 8:56am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

NEW YORK, March 28 (Reuters) - Oncolytics Biotech Inc : * Oncolytics Biotech U.S.-listed shares up 9 percent to $3.26 in premarket after lung cancer drug meets main goal of mid-stage study